We recently published a list of 10 Stocks Jump, Defy Market Uncertainties on Thursday. In this article, we are going to take ...

Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

Abbott Laboratories snagged a CE mark for its Volt pulsed field ablation catheter for atrial fibrillation several months earlier than the mid-year approval expected. The Abbott Park, Ill.-based ...

Thursday announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib).

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...